CDK4 and breast cancer: Additionally, increased PPI usage time proportion during CDK4/6i treatment was associated with a higher risk of disease progression and mortality.<h4>Conclusion</h4>The use of PPIs and H2 blockers, in combination with CDK4/6i is associated with adverse effects on PFS and OS in patients with HR+ metastatic or recurrent breast cancer in a real-world setting.